Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | URO-12: Importance of collaboration between institutions in clinical trials

Massimo Di Maio • 3 Mar 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Avelumab Niraparib
URO-12

Massimo Di Maio, PhD, University of Turin, Turin, Italy, discusses the challenges that the URO-12 trial faced, and how collaboration between instituitions helped to overcome these difficulties. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Disclosures

Massimo Di Maio reports personal fees from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Janssen, Eisai, Astellas, Merck Sharp & Dohme, Boehringer Ingelheim, research grant from Tesaro – GlaxoSmithKline.

More from Massimo Di Maio

2:20
Future of PARP inhibitors for urothelial carcinoma
Massimo Di Maio • 3 Mar 2022
2:41
Results from URO-12 trial of niraparib maintenance therapy for advanced urothelial carcinoma
Massimo Di Maio • 3 Mar 2022
1:59
Study design of URO-12 trial of niraparib as maintenance therapy for advanced urothelial carcinoma
Massimo Di Maio • 3 Mar 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals